Pages that link to "Q57422965"
Jump to navigation
Jump to search
The following pages link to Rheumatoid arthritis and cancer risk (Q57422965):
Displaying 50 items.
- Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis (Q24675306) (← links)
- Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? (Q26744032) (← links)
- Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis (Q26799036) (← links)
- Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis (Q28185207) (← links)
- Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study (Q28192013) (← links)
- Lung cancer and interstitial lung diseases: a systematic review (Q28387238) (← links)
- Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden (Q31041008) (← links)
- Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia (Q33372701) (← links)
- Non-Hodgkin lymphoma and autoimmunity: does gender matter? (Q33391942) (← links)
- Cancer biology in diabetes (Q33608038) (← links)
- Epistemology of the origin of cancer: a new paradigm (Q33631655) (← links)
- Screening for cancer in the patient with rheumatic disease (Q33722916) (← links)
- Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting (Q33734256) (← links)
- A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort (Q33760824) (← links)
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data (Q33799604) (← links)
- Summary of worldwide pediatric malignancies reported after exposure to etanercept (Q33998050) (← links)
- Malignancy in systemic lupus erythematosus: what have we learned? (Q34087859) (← links)
- A review of the application of inflammatory biomarkers in epidemiologic cancer research (Q34135803) (← links)
- Lymphoid malignancies: the dark side of B-cell differentiation (Q34162187) (← links)
- Comorbidity in rheumatoid arthritis. (Q34275967) (← links)
- The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. (Q34363241) (← links)
- Imaging of the pulmonary manifestations of systemic disease (Q34380555) (← links)
- Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? (Q34458932) (← links)
- Breast cancer risk in rheumatoid arthritis: an update meta-analysis (Q34487651) (← links)
- Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort (Q34628409) (← links)
- Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans (Q34642920) (← links)
- Some aspects of the etiology of non-Hodgkin's lymphoma (Q34941602) (← links)
- A question of transformation: the synovial fibroblast in rheumatoid arthritis (Q35111655) (← links)
- Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies (Q35120199) (← links)
- Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report (Q35144770) (← links)
- Risk of cancer among rheumatoid arthritis patients in California (Q35162890) (← links)
- Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis (Q35194346) (← links)
- Co-morbidity in rheumatoid arthritis (Q35198206) (← links)
- Lymphoproliferation in autoimmunity and Sjögren’s syndrome (Q35553396) (← links)
- Advances in targeted therapy: safety of biological agents (Q35553474) (← links)
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (Q35554823) (← links)
- Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists (Q35554865) (← links)
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas (Q35555527) (← links)
- Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. (Q35605468) (← links)
- Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study (Q35608156) (← links)
- Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports (Q35630645) (← links)
- Online training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based survey (Q35633961) (← links)
- Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis (Q35637322) (← links)
- Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model (Q35745397) (← links)
- Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. (Q35769457) (← links)
- Rheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome (Q35827560) (← links)
- Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis (Q35842626) (← links)
- The treatment of rheumatoid arthritis (Q35859217) (← links)
- Etanercept for the treatment of psoriasis and psoriatic arthritis (Q35893160) (← links)
- Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis (Q35893167) (← links)